Analyst Conference Summaries

Biotechnology Investor Aids

Vascular Biogenics

conference date: May 17, 2018 @ 5:30 AM Pacific Time

VBL Therapeutics (VBLT) Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Glioblastoma

I first bought Vascular Biogenics in June 2016 and will begin coverage with the Q1 2018 analyst conference. The stock price plunged on March 8, 2018 when the glioblastoma trial produced negative results.

March 15, 2018
May 17, 2018

Vascular Biogenics (VBLT) is a clinical-stage biotechnology company specializing in cancer therapies. It is also known as VBL Therapeutics.

Vascular Biogenics (VBLT) web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers